Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

Autor: Morita, Akimichi, Strober, Bruce, Burden, A David, Choon, Siew Eng, Anadkat, Milan J, Marrakchi, Slaheddine, Tsai, Tsen-Fang, Gordon, Kenneth B, Thaçi, Diamant, Zheng, Min, Hu, Na, Haeufel, Thomas, Thoma, Christian, Lebwohl, Mark G
Zdroj: The Lancet; October-November 2023, Vol. 402 Issue: 10412 p1541-1551, 11p
Abstrakt: Spesolimab is an anti-interleukin-36 receptor monoclonal antibody approved to treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and safety of spesolimab for GPP flare prevention.
Databáze: Supplemental Index